Public Event Detail
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-03-09MSFTMicrosoftAlpha Vantage Newsalpha_vantage_news
Event summary
Promis Neurosciences (NASDAQ:PMN) has received a "Moderate Buy" consensus recommendation from four brokerages, with an average 1-year price target of $42.67. The company has seen significant insider buying, totaling approximately $8.6 million in the last three months, and institutions own about 50.13% of the stock. Shares are trading around $23.77 with a market cap of $51.11 million.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending